ALX Oncology’s Two Drugs Near Critical Milestones in EGFR-Targeted ADC and CD47 Checkpoint Trials

ALX Oncology’s presentation at the Wells Fargo 21st Annual Healthcare Conference, held on September 9, 2026, underscored the biotech’s progress on two key oncology assets nearing pivotal clinical decision points. The company’s stock, ALXO, closed at $1.84 on regular trading, down 8% from the prior close of $2.00, but rose 1.63% after hours to $1.87, reflecting a one-year return of nearly 69%. With a fair value estimate of $2.14 and a consensus buy rating, analysts project price targets ranging from $4 to $6. The company’s cash runway extends through the first half of 2028, following a $100 million financing completed in February 2026, and a current ratio of 9.71.